Get the Stockscreener App
28.07
0.81%
-0.23
Pre-market:
28.03
-0.04
-0.14%
Harrow Inc stock is traded at $28.07, with a volume of 245.60K.
It is down -0.81% in the last 24 hours and up +17.01% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$28.30
Open:
$28.23
24h Volume:
245.60K
Relative Volume:
0.48
Market Cap:
$1.03B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-29.24
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
+6.85%
1M Performance:
+17.01%
6M Performance:
-33.86%
1Y Performance:
+67.18%
1-Day Range:
$27.50
$28.23
1-Week Range:
$24.62
$28.48
52-Week Range:
$15.97
$59.23
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
28.07 | 964.10M | 154.15M | -33.58M | -20.74M | -0.96 |
|
HLN
Haleon Plc Adr
|
11.02 | 47.07B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.65 | 71.42B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.90 | 3.34M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.27 | 42.86B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 20.05B | 16.54B | -1.64B | 749.00M | -1.45 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com India
Harrow Inc.: Opaleye management sells $150,055 in stock - Investing.com
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey
Harrow to Present at Two Investor Conferences in May - Business Wire
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga
Harrow Health, Inc. (NASDAQ:HROW) Q1 2025 Earnings Call Transcript - Insider Monkey
Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus
HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus
Where Harrow Stands With Analysts - Benzinga
HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto - GuruFocus
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - MSN
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Reven - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... By GuruFocus - Investing.com Canada
Harrow Health Reports Strong Q1 2025 Revenue Growth - TipRanks
Harrow Announces First-Quarter 2025 Financial Results - BioSpace
Transcript : Harrow, Inc., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
Harrow Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Harrow: Q1 Earnings Snapshot - CT Insider
Harrow Health Q1 2025 slides: revenue up 43% as ophthalmic portfolio expands - Investing.com
Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings: EPS of -$0.50 Misses Estimate, Revenue at $47.8M Below Forecast - GuruFocus
Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share - marketscreener.com
Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans - GuruFocus
HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW St - GuruFocus
HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW Stock News - GuruFocus
Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans | HROW Stock News - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Harrow to Report First Quarter 2025 Financial Results After Mark - GuruFocus
Examining the Future: Harrow's Earnings Outlook - Nasdaq
What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire
Invesco Ltd. Lowers Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow, Inc. (NASDAQ:HROW) Shares Sold by Wells Fargo & Company MN - Defense World
Harrow Inc (HROW) Shares Gap Down to $24.695 on Apr 28 - GuruFocus
Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - MSN
JPMorgan Chase & Co. Lowers Stock Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic L - GuruFocus
Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment - marketscreener.com
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - Morningstar
LPL Financial LLC Has $699,000 Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives Propel Success - GuruFocus
Harrow Inc (NASDAQ: HROW) Jumps 2.74%: The Most Likely Path Going Forward - Stocksregister
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire
Major Dry Eye Treatment Breakthrough: VEVYE Opens Access to 25,000+ Patients with $59 Price Tag - Stock Titan
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.37%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):